It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis.
The abstract entitled: ‘Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study’ was presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021.
Questions:
- What are the advantages of diroximel fumarate compared with dimethyl fumarate in the treatment of patients with relapsing remitting MS? (0:13)
- What is known about the incidence of flushing with dimethyl fumarate treatment? (1:02)
- What were the objectives of this analysis of the EVOLVE-MS study data? (1:42)
- What were the findings in terms of flushing incidence and severity? (2:30)
- What were the limitations of this analysis and what future studies are needed? (3:14)
Disclosures: Barry Singer has received research grant support and speaking/consulting honorarium from Biogen.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of ECTRIMS, Virtual 2021
